Zimbabwe has declined a substantial US health deal worth 367 million US dollars (272 million pounds) over five years due to the United States' insistence on confidential biological samples.
This move became public after a official document from December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesman later clarified that the US was demanding access to genetic material for research and commercial gain while refused to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged further talks to reach a deal acceptable to both sides so the country's vital HIV programme can continue.
Wider Background
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a high court suspended a similar deal with the US after concerns were filed about the safety of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to enhance openness and responsibility.
As per statements, Sixteen African countries have to date agreed to these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Declined Deal
This assistance for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation could have provided extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy via American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, with no corresponding promise of access to any medical innovations – like new medicines or tests – that could be developed from that provided information," he stated.
"Put simply, our country would provide the raw materials for scientific discovery with no assurance that the final treatments would be available to our people if a future disease outbreak emerge."
National Interest and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of one-on-one deals were disrupting systems previously established through the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with potential pandemics.
"This system is designed to ensure that when a country provides its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
The government's concerns over the US deal "are not meant as hostility towards the US," he added.
"We welcome ongoing discussions with our US partners on how future co-operation could be structured in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body expressed it acknowledged the official position, but suggested that talks must proceed given that much of the country's HIV programmes depended on international support.
"If technical issues arise, including those relating to information security or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," the group added.
The situation emphasises the ongoing challenges between receiving much-needed international aid and protecting a country's data in an ever more interconnected world.